Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LGX818 with cetuximab with or without BYL719 in BRAF-mutant metastatic colorectal cancer
NL-OMON47136Phase 2Recruiting
- Sponsor
- Array BioPharma
- Start
- Nov 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of encorafenib, cetuximab and alpelisib in colorectal cancer (CRC) (2 arms), sponsored by Array BioPharma. Primary endpoints: Incidence of dose-limiting toxicities and Progression-free survival. Started Nov 2012; status: recruiting.
02
Drugs
encorafenibcetuximabalpelisib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON47136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47136.